Drug Trial Radar · NCT06864884
A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction
Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 26, 2025
Primary completion
Feb 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- Arcato Laboratories, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side effects?
Conditions
- Acute Post Operative Pain
- Third Molar Extraction Surgery
Interventions
ARC-001Drug
Gel formulation containing investigational anesthetic.
Placebo gelDrug
Gel that contains no active ingredients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 28 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExel JBR
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.